Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rveiling is a topical regenerative skincare serum developed by Aowita Biotech, specifically formulated for skin barrier repair and tissue regeneration. The serum's primary active ingredients are high-purity salmon-derived polydeoxyribonucleotide (PDRN) and hyaluronic acid. PDRN functions as a regenerative agent by activating adenosine A2A receptors, which promotes cell proliferation, collagen synthesis, and anti-inflammatory pathways to repair damaged skin tissue. Hyaluronic acid complements this by providing deep hydration and maintaining the skin's structural integrity. While marketed as a cosmetic or regenerative skincare product, Rveiling utilizes these biological mechanisms to restore skin health and barrier function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rveiling (Aowita).